"Streptococcus pneumoniae" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A gram-positive organism found in the upper respiratory tract, inflammatory exudates, and various body fluids of normal and/or diseased humans and, rarely, domestic animals.
| Descriptor ID |
D013296
|
| MeSH Number(s) |
B03.353.750.737.872.550 B03.510.400.800.872.550 B03.510.550.737.872.550
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Streptococcus pneumoniae".
Below are MeSH descriptors whose meaning is more specific than "Streptococcus pneumoniae".
This graph shows the total number of publications written about "Streptococcus pneumoniae" by people in this website by year, and whether "Streptococcus pneumoniae" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1999 | 2 | 2 | 4 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 3 | 2 | 5 |
| 2003 | 1 | 2 | 3 |
| 2004 | 2 | 3 | 5 |
| 2005 | 2 | 0 | 2 |
| 2006 | 4 | 1 | 5 |
| 2007 | 5 | 2 | 7 |
| 2008 | 4 | 1 | 5 |
| 2009 | 2 | 0 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 9 | 0 | 9 |
| 2012 | 3 | 3 | 6 |
| 2013 | 3 | 3 | 6 |
| 2014 | 8 | 5 | 13 |
| 2015 | 5 | 2 | 7 |
| 2016 | 7 | 3 | 10 |
| 2017 | 9 | 6 | 15 |
| 2018 | 4 | 1 | 5 |
| 2019 | 8 | 2 | 10 |
| 2020 | 9 | 3 | 12 |
| 2021 | 3 | 11 | 14 |
| 2022 | 3 | 3 | 6 |
| 2023 | 4 | 7 | 11 |
| 2024 | 4 | 5 | 9 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Streptococcus pneumoniae" by people in Profiles.
-
Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: The PSERENADE project. J Infect. 2025 Mar; 90(3):106426.
-
Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study. Expert Rev Vaccines. 2025 Dec; 24(1):121-127.
-
Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis. Lancet Infect Dis. 2025 Apr; 25(4):457-470.
-
Single priming and a booster dose of 10-valent and 13-valent pneumococcal conjugate vaccine (PCV) maintains suppression of vaccine serotype colonization in South African children at 3, 4, and 5 years of age: a single-centre, open-labelled, randomized trial. Expert Rev Vaccines. 2024 Jan-Dec; 23(1):1011-1019.
-
Impact of pneumococcal conjugate vaccines on invasive pneumococcal disease-causing lineages among South African children. Nat Commun. 2024 Sep 27; 15(1):8401.
-
Demographic and pathogen characteristics of incident bacterial meningitis in infants in South Africa: A cohort study. PLoS One. 2024; 19(9):e0310528.
-
Long-term effect of pneumococcal conjugate vaccines on invasive pneumococcal disease incidence among people of all ages from national, active, laboratory-based surveillance in South Africa, 2005-19: a cohort observational study. Lancet Glob Health. 2024 Sep; 12(9):e1470-e1484.
-
Geographical migration and fitness dynamics of Streptococcus pneumoniae. Nature. 2024 Jul; 631(8020):386-392.
-
Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis. Health Technol Assess. 2024 Jul; 28(34):1-109.
-
Characterization of bacterial and viral pathogens in the respiratory tract of children with HIV-associated chronic lung disease: a case-control study. BMC Infect Dis. 2024 Jun 26; 24(1):637.